Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 15, 2015Journal of Medicinal ChemistryOpen Access

Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

VNVincent C.O. NjarABAngela Brodie

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Njar et al. (2015) studied this question.

synapsesocial.com/papers/6a93c643239a5ba871d7c8a7https://doi.org/10.1021/jm501239f
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 117α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response2008 · 64 citations
  2. 2Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:  Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model2005 · 248 citations